Why the study?
Does enteric-coated aspirin spare peripheral vascular cyclooxygenase compared to regular aspirin tablets in humans?
Does enteric-coated aspirin spare peripheral vascular cyclooxygenase compared to regular aspirin tablets in humans?
Enteric-coated aspirin does not spare peripheral vascular cyclooxygenase compared to regular aspirin tablets, despite demonstrating a presystemic antiplatelet effect.
No takes yet. Share an insight, caveat, or question.
Enteric-coated aspirin does not spare vascular prostacyclin; leaves open formulation effects on net clinical outcomes.
Cerletti et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: